← SynDRA
GEDATOLISIB
SynDRA canonical compound SYN0020484 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PIK3CA |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- MTOR
- PIK3CA
- PIK3CG
- PIK3CB
- PIK3CD
- PIK3R1
- PIK3R2
- PIK3R3
- PIK3R5
Mechanisms of action (all sources)
- MTOR inhibitor
- PI3K inhibitor
- Serine/threonine-protein kinase mTOR inhibitor
- PIK3R1 INHIBITOR
- PIK3CB INHIBITOR
- PIK3CG INHIBITOR
- PIK3CA INHIBITOR
- PIK3R2 INHIBITOR
- PIK3CD INHIBITOR
- PIK3R5 INHIBITOR
- PIK3R3 INHIBITOR
- MTOR MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PIK3CD
- PIK3C3
- PIK3C2B
- PI4KB
- PHKG2
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PCYT1A
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- PIK3CB
- PIM1
- NUAK2
- PIP4K2A
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- OLA1
- NTRK1
- PRKCI
- MCM4
Cross-references
Synonyms
- PF-05212384
- PKI-587
- PF 05212384
- PKI 587
- PKI587
- 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea
- UNII-96265TNH2R
- PF-05212384 (PKI-587)
- CHEMBL592445
- 96265TNH2R
- N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea
- Gedatolisib (PF-05212384, PKI-587)
- Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-
- gedatolisibum
- RefChem:922134
- DTXCID3075048
- MFCD16875679
- PKI-587; PF-05212384
- Gedatolisib [USAN:INN]
- Gedatolisib (PKI-587)
- C32H41N9O4
- PK 587
- PK 1587
- Gedatolisib(PKI-587)
- GEDATOLISIB [INN]
- Gedatolisib (USAN/INN)
- GEDATOLISIB [USAN]
- Gedatolisib(PKI-587)?
- SCHEMBL32393
- GEDATOLISIB [WHO-DD]
- GTPL7940
- orb1306926
- EX-A028
- DWZAEMINVBZMHQ-UHFFFAOYSA-N
- GLXC-06796
- HMS3748M11
- BDBM50308135
- NSC758256
- NSC801014
Look up GEDATOLISIB in the interactive SynDRA portal →